Newly-released Genomics industry analysis report by Future Market Insights shows that global sales of Genomics in 2021 were held at US$ 24.3 Billion. With 19.8%, the projected market growth from 2022 to 2032 is expected to be significantly higher than the historical growth. Functional Genomics is expected to be the highest revenue-generating type, expected to grow at a CAGR of 23% from 2022 to 2032.
| Attribute | Details |
|---|---|
| Global Genomics Market (2022) | US$ 28.5 Billion |
| Global Genomics Market (2032) | US$ 170.5 Billion |
| Global Genomics Market CAGR (2022 to 2032) | 19.8% |
| USA Genomics Market CAGR (2022 to 2032) | 22% |
| Key Companies Profiled |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Genomics industry research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of the Genomics industry increased at around 16% CAGR, wherein, countries such as the USA, United Kingdom, China, South Korea, and Japan held a significant share in the global market. Owing to this, the Genomics market is projected to grow at a CAGR of 19.8% over the coming 10 years.
Scientists have researched genetic vulnerability and intensity to coronavirus disease 2 by using scientific studies and exploiting existing databases of genetic information. Genome-wide association studies (GWAS) using genomic modeling and multi-omic approaches have revealed different biological networks and social influences on diseases.
Similarly, genomic data such as polygenic risk scores (PRS), ABO blood groups, and HLA haplotypes may be used to discover comorbidities, resistance, and susceptibility to suspected COVID-19 patients. Biobanks that connect electronic health records (EHRs) to genetic data can be utilized to research the association between genomic factors of suspected SARS-CoV-2 patients' health histories.
The COVID-19 Host Genetics Initiative, led by researchers at FIMM, aims to encourage the human genetics community to the analysis of, share, and collect data in order to promote research into elements that explain the severity of COVID-19, the susceptibility of a person to the infection, and its possible outcomes. DeCODE genetics, an Icelandic genomics solutions provider, used SARS-CoV-2 genome analysis to track the virus's propagation.
In addition, the business has also teamed up with the Icelandic government to sequence the genomes of viral hosts. Similarly, the Greek government supported the COVID-19-GR program, which genotyped 3,500 COVID-19 patients, performed WGS on the SARS-CoV-2 genome received from these patients, and performed immunogenomic analysis. The whole collection of these data, as well as extensive clinical information, is available from the Greek COVID-19 registry.
In the foreseeable future, prenatal genetic screening techniques are likely to grow rapidly. Because these programs assist pregnant mothers in spotting genetic problems in their infants, this is the case. Within the next ten years, every newborn's genome is projected to be sequenced and preserved in an electronic medical record. Emerging firms such as Counsyl and Natera to maintain their competitive advantage in the sector, measuring the future market possibilities of genomics in the newborn screening program, have released several genetic tests.
Principal Consultant
Research projects in the region involving the use of genomic technology and genomic sequencing are increasing, and the idea is that the growth of one of these initiatives will continue at 20% in the subsequent years. One noteworthy research study is represented by the GenomeAsia 100K Project, which uses whole-genome sequencing (WGS) to facilitate discoveries regarding Asians.
The method was tested throughout the region. Furthermore, by expanding the number of approvals, helpful regulatory authorities contribute to market growth. The National Cancer Center (NCC) of Japan, in collaboration with Foundation Medicine and Chugai Pharmaceutical, Ltd., announced in February 2020 that FoundationOneLiquid would be used in the third stage of Japan's cancer genomic screening consortium. The market for genomic testing services in Japan grew as a result of this.
The USA dominated the global market with a share of over 30% in 2021, due to an increase in the number of research programs, numerous strategic alliances, and a higher share of FDA approvals by the USA FDA. In this market, reimbursement and usage policy decisions may increase the adoption of genetic tests.
In January 2020, Color Genomics, Inc., in collaboration with NorthShore University Health System, implemented clinical genomics into routine care under the United States health program. Furthermore, the company also aided Sanford in its genomics initiative, Imagenetics, to enhance medical decision-making.
The market in the United Kingdom is expected to account for US$ 7.5 Billion by 2032. From 2022 to 2032, the market in the country is expected to grow at a CAGR of 20.4% to gross an absolute dollar opportunity of US$ 6.3 Billion.
In Japan, the market is projected to reach a valuation of around US$ 6 Billion by 2032. The market is expected to score an absolute dollar opportunity of around US$ 5 Billion, growing at a CAGR of 19.3% from 2022 to 2032.
The market in South Korea is expected to reach a valuation of US$ 2.6 Billion by 2032. Growing at a CAGR of 16.2, the market is expected to register an absolute dollar opportunity of US$ 2 Billion.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Functional genomics, with a revenue share of 32% in 2021, held the highest revenue share. Real-time PCR was the most profitable method in functional genomics. Real-time quantitative PCR has assisted the absolute quantification of genetic components in genomic DNA. This method was utilized to see if tissue genomic DNA could be used as a global external reference for speeding up the measurement of any target sequence in different species' genomes.
This approach, when combined with reverse transcription PCR, allows researchers to measure low-abundance mRNA, allowing them to calculate relative gene expression at a specific time. When it comes to detecting minor changes in gene expression, this technique has been shown to be more sensitive than array technology. As a result, its acceptance rate is steadily increasing. In high-throughput research, however, it requires additional input and is found to be less adaptive.
The products category led the market in 2021 owing to the continual launches of nucleic acid extraction reagents and kits by prominent manufacturers. In May 2020, Omega Bio-tek, Inc. introduced the Mag-Bind Viral RNA Xpress Kit. Its kit for isolating viral RNA rapidly and accurately in nasopharyngeal swabs was certified for use in June 2020.
The release of a new purification kit allows an increase in the range of degradation kits used for COVID-19 testing. Similarly, the PHASE Scientific network launched in April 2020 the PHASIFY VIRAL RNA Extraction Kit, which is used to assist in the diagnosis of and pre-emptive control of coronavirus.
This kit helps to purify and concentrate viral nucleic acid found in Patient-Derived Viral Transposon Media (VTM) samples. Similarly, Tent the lack of Omnia Verum was publicized in anticipation of the release of a new kit to simplify the extraction of viral RNA for purposes of helping with the hunt for the coronavirus in October 2020.
Pharmaceutical and biotechnology firms accounted for more than 60% of the market in 2021. Because of the growing number of genetic research investigations, genomic technologies are in high demand among pharmaceutical and biotechnology corporations. Because genomics is important in drug research and development, multiple companies are using genomic approaches to make the process easier and more efficient.
Over the last few years, companies have begun to offer direct-to-consumer genomic tests, resulting in a shift in business methods. Personal genomics companies generate genomic data that pharmaceutical companies are interested in. Owing to the accessible data analysis and the availability of cheaper data gathering, several new companies joined the genomics market to meet the growing demand. Furthermore, the need for enhanced gene-editing tools in the market is increasing among biotechnology companies.
Biotechnology businesses are forging strategic alliances or licensing agreements to acquire access to this technology. In October 2020, Merck licensed CRISPR technology to Takara Bio USA, Inc. and PanCELLa, Canada. These licenses are intended to boost drug discovery and, as a result, speed up the development of novel treatments.
Key players in the genomics market are purchasing smaller businesses in order to enhance their products in line with the latest innovations. Illumina, Inc., for example, acquired Bluebee in June 2020 to improve genetic analysis. Bluebee's cloud capabilities are projected to lower the costs of sharing, storing, and maintaining genetic data in new products.
The growing number of brands offering cutting-edge technology Genomics, continuous development of characteristics offering the best consumer experience and at prices suitable for different income groups, and a growing e-commerce sector all contribute to market growth.
The key players in the market include Thermo Fisher Scientific, Agilent Technologies, Beijing Genomics Institute, Bio-Rad Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd., GE Healthcare, Illumina Inc., Oxford Nanopore Technologies, QIAGEN N.V., Myriad Genetics, Inc., Quest Diagnostics Incorporated, Eppendorf AG, and Eurofins Scientific.
Some of the recent developments of key Genomics providers are as follows:
Similarly, recent developments related to companies offering Genomics have been tracked by the team at Future Market Insights, which are available in the full report.
The global Genomics market is worth more than US$ 24.3 Billion at present.
The value of Genomics is projected to increase at a CAGR of around 19.8% from 2022 to 2032.
The value of Genomics increased at a CAGR of around 16% from 2017 to 2021.
One of the primary driving forces that have boosted genomic companies' investment in the sector is technological breakthroughs in genetic tools and molecular diagnostics.
The top five players in the Genomics market include Thermo Fisher Scientific, Agilent Technologies, Beijing Genomics Institute, Bio-Rad Laboratories, and Danaher Corporation
The top 5 countries driving demand for Genomics are the USA, the United Kingdom, China, Japan, and South Korea.
North America accounted for over 30% of global Genomics demand in 2021.
1. Executive Summary | Genomics Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Investment Feasibility Matrix 3.6. PESTLE and Porter’s Analysis 3.7. Regulatory Landscape 3.7.1. By Key Regions 3.7.2. By Key Countries 3.8. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Application, 2017 to 2021 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2022 to 2032 5.3.1. Functional Genomics 5.3.1.1. Real-time PCR 5.3.1.2. Transfection 5.3.1.3. SNP Analysis 5.3.1.4. Mutational Analysis 5.3.1.5. Microarray Analysis 5.3.1.6. RNA Interference 5.3.2. Pathway Analysis 5.3.2.1. Microarray Analysis 5.3.2.2. Bead-based Analysis 5.3.2.3. Proteomics Tools (2-D PAGE; yeast 2-hybrid studies) 5.3.2.4. Real-time PCR 5.3.2.5. Mass Spectrometry 5.3.3. Biomarker Discovery 5.3.3.1. DNA Sequencing 5.3.3.2. Microarray Analysis 5.3.3.3. Real-time PCR 5.3.3.4. Mass Spectrometry 5.3.3.5. Other Biomarker Discoveries 5.3.4. Epigenetics 5.3.4.1. Bisulfite Sequencing 5.3.4.2. Microarray Analysis 5.3.4.3. Chromatin Immunoprecipitation (ChIP & ChIP-Seq) 5.3.4.4. Methylated DNA Immunoprecipitation (MeDIP) 5.3.4.5. Other Epigenetics 5.3.5. Other Application & Technologies 5.4. Y-o-Y Growth Trend Analysis By Application, 2017 to 2021 5.5. Absolute $ Opportunity Analysis By Application, 2022 to 2032 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Deliverable 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Deliverable, 2017 to 2021 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Deliverable, 2022 to 2032 6.3.1. Products 6.3.2. Services 6.4. Y-o-Y Growth Trend Analysis By Deliverable, 2017 to 2021 6.5. Absolute $ Opportunity Analysis By Deliverable, 2022 to 2032 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End-use 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End-use, 2017 to 2021 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-use, 2022 to 2032 7.3.1. Pharmaceutical and Biotechnology Companies 7.3.2. Hospitals and Clinics 7.3.3. Academic and Government Institutes 7.3.4. Clinical Research 7.3.5. Other End Users 7.4. Y-o-Y Growth Trend Analysis By End-use, 2017 to 2021 7.5. Absolute $ Opportunity Analysis By End-use, 2022 to 2032 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Application 9.2.3. By Deliverable 9.2.4. By End-use 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Application 9.3.3. By Deliverable 9.3.4. By End-use 9.4. Key Takeaways 10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Application 10.2.3. By Deliverable 10.2.4. By End-use 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Application 10.3.3. By Deliverable 10.3.4. By End-use 10.4. Key Takeaways 11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Russia 11.2.1.7. Rest of Europe 11.2.2. By Application 11.2.3. By Deliverable 11.2.4. By End-use 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Application 11.3.3. By Deliverable 11.3.4. By End-use 11.4. Key Takeaways 12. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. India 12.2.1.4. South Korea 12.2.1.5. Australia 12.2.1.6. Rest of Asia Pacific 12.2.2. By Application 12.2.3. By Deliverable 12.2.4. By End-use 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Application 12.3.3. By Deliverable 12.3.4. By End-use 12.4. Key Takeaways 13. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 13.2.1. By Country 13.2.1.1. South Africa 13.2.1.2. Saudi Arabia 13.2.1.3. United Arab Emirates(UAE) 13.2.1.4. Israel 13.2.1.5. Rest of Middle East and Africa(MEA) 13.2.2. By Application 13.2.3. By Deliverable 13.2.4. By End-use 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Application 13.3.3. By Deliverable 13.3.4. By End-use 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. USA 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2021 14.1.2.1. By Application 14.1.2.2. By Deliverable 14.1.2.3. By End-use 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2021 14.2.2.1. By Application 14.2.2.2. By Deliverable 14.2.2.3. By End-use 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2021 14.3.2.1. By Application 14.3.2.2. By Deliverable 14.3.2.3. By End-use 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2021 14.4.2.1. By Application 14.4.2.2. By Deliverable 14.4.2.3. By End-use 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2021 14.5.2.1. By Application 14.5.2.2. By Deliverable 14.5.2.3. By End-use 14.6. United Kingdom 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2021 14.6.2.1. By Application 14.6.2.2. By Deliverable 14.6.2.3. By End-use 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2021 14.7.2.1. By Application 14.7.2.2. By Deliverable 14.7.2.3. By End-use 14.8. Spain 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2021 14.8.2.1. By Application 14.8.2.2. By Deliverable 14.8.2.3. By End-use 14.9. Italy 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2021 14.9.2.1. By Application 14.9.2.2. By Deliverable 14.9.2.3. By End-use 14.10. Russia 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2021 14.10.2.1. By Application 14.10.2.2. By Deliverable 14.10.2.3. By End-use 14.11. China 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2021 14.11.2.1. By Application 14.11.2.2. By Deliverable 14.11.2.3. By End-use 14.12. Japan 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2021 14.12.2.1. By Application 14.12.2.2. By Deliverable 14.12.2.3. By End-use 14.13. India 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2021 14.13.2.1. By Application 14.13.2.2. By Deliverable 14.13.2.3. By End-use 14.14. South Korea 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2021 14.14.2.1. By Application 14.14.2.2. By Deliverable 14.14.2.3. By End-use 14.15. Australia 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2021 14.15.2.1. By Application 14.15.2.2. By Deliverable 14.15.2.3. By End-use 14.16. South Africa 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2021 14.16.2.1. By Application 14.16.2.2. By Deliverable 14.16.2.3. By End-use 14.17. Saudi Arabia 14.17.1. Pricing Analysis 14.17.2. Market Share Analysis, 2021 14.17.2.1. By Application 14.17.2.2. By Deliverable 14.17.2.3. By End-use /p> 14.18. United Arab Emirates(UAE) 14.18.1. Pricing Analysis 14.18.2. Market Share Analysis, 2021 14.18.2.1. By Application 14.18.2.2. By Deliverable 14.18.2.3. By End-use 14.19. Israel 14.19.1. Pricing Analysis 14.19.2. Market Share Analysis, 2021 14.19.2.1. By Application 14.19.2.2. By Deliverable 14.19.2.3. By End-use 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Application 15.3.3. By Deliverable 15.3.4. By End-use 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Thermo Fisher Scientific, Inc. 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Agilent Technologies 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. Beijing Institute (BGI) 16.1.3.1. Overview& 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Bio-Rad Laboratories, Inc. 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Danaher Corporation 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. F. Hoffmann-La Roche Ltd. 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. GE Healthcare 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. Illumina Inc. 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. Oxford Nanopore Technologies 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. QIAGEN N.V. 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 16.1.11. Myriad Genetics, Inc. 16.1.11.1. Overview 16.1.11.2. Product Portfolio 16.1.11.3. Profitability by Market Segments 16.1.11.4. Sales Footprint 16.1.11.5. Strategy Overview 16.1.11.5.1. Marketing Strategy 16.1.12. Quest Diagnostics Incorporated 16.1.12.1. Overview 16.1.12.2. Product Portfolio 16.1.12.3. Profitability by Market Segments 16.1.12.4. Sales Footprint 16.1.12.5. Strategy Overview 16.1.12.5.1. Marketing Strategy 16.1.13. Eppendorf AG 16.1.13.1. Overview 16.1.13.2. Product Portfolio 16.1.13.3. Profitability by Market Segments 16.1.13.4. Sales Footprint 16.1.13.5. Strategy Overview 16.1.13.5.1. Marketing Strategy 16.1.14. Eurofins Scientific 16.1.14.1. Overview 16.1.14.2. Product Portfolio 16.1.14.3. Profitability by Market Segments 16.1.14.4. Sales Footprint 16.1.14.5. Strategy Overview 16.1.14.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Genomics Market
